REG - Oxford Biomedica PLC - Person Closely Associated Dealing

Oxford BioMedicaAnnouncement

30/04/2025 17:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250430:nRSd9010Ga&default-theme=true

RNS Number : 9010G  Oxford Biomedica PLC  30 April 2025

 

Person Closely Associated Dealing

 

Oxford, UK - 30 April 2025: OXB (LSE: OXB) (the "Company"), a global quality
and innovation-led cell and gene therapy CDMO, today announces that Pippa
Radcliffe, a person closely associated with Dr. Kyriacos Mitrophanous, Chief
Innovation Officer of the Company, exercised 1,209 options at nil exercise
price and disposed 1,209 shares at £2.9785 per share on 30 April 2025.

The below notifications, made in accordance with the requirements of the EU
Market Abuse Regulation, give further details of the transaction.

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")/person
     closely associated with them ("PCA")
 a)  Name                                     Pippa Radcliffe
 2.  Reason for the notification
 a)  Position/status                          This notification concerns Pippa Radcliffe in her capacity as a person closely
                                              associated with a person discharging managerial responsibilities. The person
                                              discharging managerial responsibilities is Dr. Kyriacos Mitrophanous, Chief
                                              Innovation Officer of the Company. The association arises by virtue of Pippa
                                              Radcliffe being the spouse of Dr. Kyriacos Mitrophanous.
 b)  Initial notification/ amendment          Initial Notification
 3.  Details of the Issuer
 a)  Full name of the entity                  Oxford Biomedica plc
 b)  LEI code                                 213800S1GVQNXQ15K851
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Date of the transaction                  2025-04-30
 b)  Description of the financial instrument  Ordinary Shares of 50 pence each

 c)  Identification code                      ISIN: GB00BDFBVT43
 d)  Nature of the transaction                Exercise of Options at nil exercise price
 e)  Place of the transaction                 London Stock Exchange, Main Market (XLON)
 f)  Currency                                 GBP - British pound
 g)  Price(s) and volumes(s)                  Price(s)  Volume(s)

                                        £0.00     1,209

 h)  Aggregated information

     -    Aggregate volume                    1,209

     -    Price                               £0.00

     -    Aggregated total                    £0.00

h)

Aggregated information

-    Aggregate volume

-    Price

-    Aggregated total

 

1,209

£0.00

£0.00

 

 

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")/person
     closely associated with them ("PCA")
 a)  Name                                     Pippa Radcliffe
 2.  Reason for the notification
 a)  Position/status                          This notification concerns Pippa Radcliffe in her capacity as a person closely
                                              associated with a person discharging managerial responsibilities. The person
                                              discharging managerial responsibilities is Dr. Kyriacos Mitrophanous, Chief
                                              Innovation Officer of the Company. The association arises by virtue of Pippa
                                              Radcliffe being the spouse of Dr. Kyriacos Mitrophanous.
 b)  Initial notification/ amendment          Initial Notification
 3.  Details of the Issuer
 a)  Name                                     Oxford Biomedica plc
 b)  LEI code                                 213800S1GVQNXQ15K851
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Date of the transaction                  2025-04-30
 b)  Description of the financial instrument  Ordinary Shares of 50 pence each

 c)  Identification code                      ISIN: GB00BDFBVT43
 d)  Nature of transaction                    Sale of shares
 e)  Place of the transaction                 London Stock Exchange, Main Market (XLON)
 f)  Currency                                 GBP - British pound
 g)  Price(s) and volumes(s)                  Price(s)  Volume(s)
                                              £2.9785   1,209
 h)  Aggregated information

     -    Aggregate volume                    1,209

     -    Price

                                              £2.9785

     -    Aggregated total

                                              £3,601.01

h)

Aggregated information

-    Aggregate volume

 

-    Price

 

-    Aggregated total

 

 

1,209

 

 

£2.9785

 

£3,601.01

 

-Ends-

 

Enquiries:

 

OXB:

Natalie Walter, Company Secretary - T: +44 (0) 1865 783 000 / E: cosec@oxb.com

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Angela Gray / Davide Salvi

 

 

About OXB

 

OXB (LSE: OXB) is a global quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of
experience in viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector development
and manufacturing expertise in lentivirus, adeno-associated virus (AAV),
adenovirus and other viral vector types. OXB's world-class capabilities span
from early-stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.

OXB offers a vast number of unique technologies for viral vector
manufacturing, including a 4th generation lentiviral vector system (the
TetraVecta™ system), dual plasmid system for AAV production, suspension and
perfusion process using process enhancers and stable producer and packaging
cell lines.

 

OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has
bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France and near Boston, MA, US. Learn more at www.oxb.com
(http://www.oxb.com) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica) and YouTube.
(https://www.youtube.com/oxfordbiomedica)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHSDWFISEISELL